Skip to main content

Third Wave Inks Marketing, Research Pact with DCL Medical Labs

NEW YORK (GenomeWeb News) – Third Wave Technologies today announced that it has teamed up with DCL Medical Laboratories to showcase its existing molecular diagnostic products and collaborate on research of future assays.
Under the agreement, Indianapolis-based DCL will offer Third Wave’s molecular diagnostic assays and have early access to new assays and equipment developed by the Madison, Wis.-based firm. In addition, Third Wave intends to establish a research and development lab at DCL for joint product research. The lab also will include a customer demonstration facility for Third Wave’s products.
DCL specializes in women’s health and human papillomavirus testing, which is also a focus for Third Wave.
Third Wave recently announced that it will submit data from clinical trials on its HPV molecular diagnostic tests with the US Food and Drug Administration in April. The firm will seek FDA clearance for a high-risk HPV test to be used in combination with a Pap test as well as an HPV genotyping test.
Terms of the alliance were not disclosed.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.